Genital Herpes - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463987 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Genital Herpes - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2019, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 7, 15 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Genital Herpes - Overview

Genital Herpes - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Genital Herpes - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Genital Herpes - Companies Involved in Therapeutics Development

Abivax SA

Admedus Ltd

AiCuris GmbH & Co KG

Astellas Pharma Inc

Auritec Pharmaceuticals Inc

Biomere LLC

BlueWillow Biologics Inc

ISR Immune System Regulation Holding AB

NanoViricides Inc

Profectus BioSciences Inc

Redbiotec AG

Sanofi Pasteur SA

Stabilitech Biopharma Ltd

Starpharma Holdings Ltd

United BioPharma Inc

Vaccibody AS

Vaxart Inc

Vir Biotechnology Inc

Genital Herpes - Drug Profiles

ABX-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acyclovir SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amenamevir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSV-529 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide for Genital Herpes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pritelivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLV-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Genital Herpes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

squaric acid dibutyl ester - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMTX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Genital Herpes - Dormant Projects

Genital Herpes - Discontinued Products

Genital Herpes - Product Development Milestones

Featured News & Press Releases

Sep 20, 2019: New Penn-Developed Vaccine Prevents Herpes in Mice, Guinea Pigs

Jul 23, 2019: BlueWillow Biologics awarded patent for intranasal genital herpes vaccine

Jul 23, 2019: BlueWillow Biologics awarded patent for intranasal genital herpes vaccine

May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study

Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data

Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging

Feb 03, 2016: Model helps decide drug dose for clinical testing

Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine

Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015

Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences

Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection

Oct 02, 2014: Admedus Announces Further Data From Herpes Simplex Vaccine Trial

Feb 03, 2014: Admedus Herpes Interim Phase I Results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463987 | GMDHC11435IDB

Number of Pages

98

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
18-03-2019

$2,000 USD

Published by Global Markets Direct
14-08-2018

$2,000 USD

Published by Global Markets Direct
20-02-2018

$2,000 USD

Published by Global Data
30-08-2017

$2,500 USD

Published by Global Markets Direct
22-08-2017

$2,000 USD

Published by Global Markets Direct
22-03-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Genital Herpes - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.